Trial Profile
A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2012
Price :
$35
*
At a glance
- Drugs Torcetrapib/atorvastatin (Primary) ; Atorvastatin
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- 05 Dec 2006 Status change
- 12 Oct 2006 Status change
- 06 Nov 2005 New trial record.